Few children with SDB/adenotonsillar
hypertrophy and adenotonsillar infections did not undergo
T&A (179 of 4276, or 4%), but, as a group, these
children had the greatest median costs
Increased costs for
antibiotics and asthma/allergy medications in children with
SDB/adenotonsillar hypertrophy and adenotonsillar infections
resulted in drug costs that were nearly 3 times greater
than in children with SDB/adenotonsillar hypertrophy but
without adenotonsillar infections. The importance of recurrent
infections as a driver of greater costs in children with
SDB/adenotonsillar hypertrophy is underrecognized but the
interplay between SDB, recurrent chest infections, and severe
asthma has been previously reported